People · Operator
Named in public records as an officer, director or promoter · active 2010–2020 · Healthtech, Other Health Care, Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RefleXion Medical, Inc. | — | Healthtech | Series D+ | $413.0M | $1.3B | 2016 |
| NeuMoDx Molecular, Inc. | — | Other Health Care | Series B | $54.8M | $444.0M | 2014 |
| Aureon Biosciences, Inc. | — | Biotechnology | Series B | $51.3M | $668.2M | 2010 |
| Strata Oncology, Inc. | — | Pharma | Series A | $29.2M | $27.0M | 2018 |
| DVS Sciences, Inc. | — | Biotechnology | Series A | $4.1M | $149.4M | 2010 |
William Burkoth at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Burkoth on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeffrey Williams | 2 | 10 |
| Jan Garfinkle | 2 | 7 |
| Nicole Walker | 2 | 4 |
| Kevin Johnson | 1 | 12 |
| Nael Kassar | 1 | 11 |
| David Rubin | 1 | 11 |
| James Pavlik | 1 | 9 |
| Christopher O'Donnell | 1 | 8 |
| FRED MOLL | 1 | 8 |
| Greg Garfield | 1 | 8 |
| Andrew J. Schwab | 1 | 7 |
| ANTOINE PAPIERNIK | 1 | 6 |
| Renee Ryan | 1 | 6 |
| Edward Michael | 1 | 6 |
| Jay Watkins | 1 | 6 |
| Keith Flaherty | 1 | 5 |
| Matthew Hobart | 1 | 4 |
| Alice Schroeder | 1 | 2 |
| Akshay Nanduri | 1 | 2 |
| Frank J. Witney | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.